Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Neha Panjwani

BIZARRE: Is moderna stock underperforming the dow | Mind Blowing Facts

Cambridge, Massachusetts-based Moderna, Inc. (MRNA), a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. The company is valued at $16.1 billion by market cap. 

Companies worth $10 billion or more are generally described as “large-cap stocks,” and MRNA perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. Moderna's ability to leverage its mRNA technology in the respiratory vaccine market gives the company a strategic advantage due to its quick development and potential for combination vaccines.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.